Von Maksym Misichenko · Nasdaq ·
Was KI-Agenten über diese Nachricht denken
Panelists agree that 13F data has limitations and may not fully reflect institutional conviction towards AXP. They debate the significance of recent share increases, with some seeing it as a 'flight to quality' ahead of a potential slowdown, while others interpret it as a bullish signal. The regulatory risk around merchant discount rates is a key concern, potentially capping multiple expansion.
Risiko: Regulatory risk around merchant discount rates, which could lead to margin compression or offset any upside from spend growth.
Chance: Potential re-rating if Q2 earnings confirm travel/cross-border strength, as suggested by Grok.
Diese Analyse wird vom StockScreener-Pipeline generiert — vier führende LLM (Claude, GPT, Gemini, Grok) erhalten identische Prompts mit integrierten Anti-Halluzinations-Schutzvorrichtungen. Methodik lesen →
Bei Holdings Channel haben wir die neueste Charge der 56 aktuellsten 13F-Einreichungen für den Berichtszeitraum 31.03.2026 überprüft und festgestellt, dass American Express Co. (Symbol: AXP) von 24 dieser Fonds gehalten wurde. Wenn Hedgefonds-Manager scheinbar gleich denken, finden wir es eine gute Idee, genauer hinzusehen.
Bevor wir fortfahren, ist es wichtig darauf hinzuweisen, dass 13F-Einreichungen nicht die ganze Geschichte erzählen, da diese Fonds nur verpflichtet sind, ihre *Long*-Positionen bei der SEC offenzulegen, aber nicht ihre *Short*-Positionen. Ein Fonds, der beispielsweise durch Leerverkäufe von Calls eine bärische Wette gegen eine Aktie eingeht, könnte auch eine gewisse Menge an Aktien halten, während er um seine allgemeine bärische Position herum handelt. Diese Long-Komponente könnte in einer 13F-Einreichung erscheinen und jeder könnte annehmen, der Fonds sei bullisch, aber dies erzählt nur einen Teil der Geschichte, *da die bärische/Short-Seite der Position nicht sichtbar ist*.
Nachdem wir diesen Vorbehalt gemacht haben, glauben wir, dass die Betrachtung von *Gruppen* von 13F-Einreichungen aufschlussreich sein kann, insbesondere beim Vergleich eines Anlagezeitraums mit einem anderen. Lassen Sie uns im Folgenden die Veränderung der AXP-Positionen für diese neueste Charge von 13F-Einreichern betrachten:
In Bezug auf die gehaltenen Aktien zählen wir, dass 5 der oben genannten Fonds ihre bestehenden AXP-Positionen vom 31.12.2025 bis zum 31.03.2026 erhöht haben, während 14 ihre Positionen verringert haben.
Über diese spezifischen Fonds in dieser einen Charge der aktuellsten Einreicher hinaus haben wir die aggregierte Anzahl der AXP-Aktien aller Fonds ermittelt, die AXP im Berichtszeitraum 31.03.2026 hielten (von den insgesamt 3.956, die wir uns angesehen haben). Wir verglichen diese Zahl dann mit der Gesamtsumme der AXP-Aktien, die dieselben Fonds zum Berichtszeitraum 31.12.2025 hielten, um zu sehen, wie sich die aggregierte Aktienanzahl, die von Hedgefonds gehalten wird, für AXP entwickelt hat. Wir stellten fest, dass die Fonds zwischen diesen beiden Zeiträumen ihre Bestände um insgesamt 3.958.896 Aktien erhöhten, von 57.432.618 auf 61.391.514, was einer Erhöhung der Aktienanzahl von etwa 6,89% entspricht. Die insgesamt drei Top-Fonds, die AXP am 31.03.2026 hielten, waren:
| » | Fonds | Gehaltene AXP-Aktien |
|---|---|---|
| 1. | Fisher Asset Management LLC | 9.250.373 |
| 2. | Nuveen LLC | 5.590.781 |
| 3. | UBS Group AG | 4.566.249 |
| 4-10 | Finden Sie die vollständige Top 10 Hedgefonds, die AXP halten | » |
Wir werden weiterhin die neuesten 13F-Einreichungen von Hedgefonds-Managern verfolgen und Ihnen interessante Geschichten liefern, die sich aus der Betrachtung der aggregierten Informationen über Gruppen von Managern zwischen den Einreichungszeiträumen ergeben. Während die Betrachtung einzelner 13F-Einreichungen aufgrund der reinen Long-Natur der Informationen manchmal irreführend sein kann, kann die Gesamtsumme über *Gruppen* von Fonds von einem Berichtszeitraum zum nächsten viel aufschlussreicher und relevanter sein und interessante Aktienideen liefern, die weitere Recherchen verdienen, wie z.B. American Express Co. (Symbol: AXP).
10 S&P 500 Komponenten, die Hedgefonds kaufen »
##### Siehe auch:
YTD-Rendite
INMB Durchschnittliche Jahresrendite
Fusionen und Übernahmen
Die hier geäußerten Ansichten und Meinungen sind die Ansichten und Meinungen des Autors und spiegeln nicht notwendigerweise die von Nasdaq, Inc. wider.
Vier führende AI-Modelle diskutieren diesen Artikel
"The net increase in institutional ownership reflects a flight to quality rather than a fundamental growth catalyst, leaving AXP vulnerable to macroeconomic slowdowns."
The 6.89% aggregate increase in AXP holdings among institutional filers suggests a defensive rotation into high-quality financials. American Express benefits from a premium consumer base that remains resilient despite inflationary pressures, providing a wider net interest margin buffer than peers. However, the divergence between the 14 funds decreasing positions and the aggregate share increase indicates a 'smart money' split. Investors are likely betting on AXP’s superior credit quality, but the 13F data is a lagging indicator. With AXP trading near historical valuation multiples, the upside is capped unless we see a significant acceleration in card member spending volume or a pivot in the Fed's interest rate trajectory.
The aggregate increase in share count could simply reflect institutional rebalancing to match benchmark weightings rather than a conviction-based bullish thesis on AXP's underlying credit performance.
"Aggregate hedge fund AXP ownership rose 6.89% QoQ despite mixed batch signals, pointing to underlying institutional accumulation in a premium financial name."
Hedge funds boosted aggregate AXP holdings by 6.89% QoQ to 61.4M shares as of Q1 2026, with Fisher Asset, Nuveen, and UBS as top owners—suggesting institutional conviction in AmEx's affluent customer base and resilient fee revenue amid sticky consumer spending. While 14 of 19 recent filers trimmed (vs. 5 adding), the broader cohort's net buying outweighs that, potentially foreshadowing re-rating if Q2 earnings confirm travel/cross-border strength. Caveat: 13Fs lag 45 days and hide shorts, so pair with options flow for full picture.
This net buying could mask widespread short overlays or profit-taking after AXP's strong run, as 14/19 filers cut stakes amid macro risks like slowing consumer credit growth. Lagging data ignores recent Fed signals or delinquency upticks that could pressure margins.
"Aggregate 13F share increases are a weak buy signal when most funds reduced positions, the largest holders are index trackers, and short/derivative positions remain invisible."
The article's headline—'hedge funds buying AXP'—rests on a 6.89% aggregate share increase across 3,956 funds over Q1 2026. But this is mechanically weak evidence. First, the article itself admits 13F data omits short positions, hedges, and derivatives—so 'long shares up 4M' could mask a $2B bearish derivatives position. Second, 5 of 24 funds in the sample *increased* positions while 14 *decreased*—that's a 5:14 ratio suggesting net skepticism, not conviction. Third, Fisher, Nuveen, and UBS are passive/index-tracking shops; their AXP holdings likely track S&P 500 weighting, not active conviction. A 6.89% increase in a rising market is noise, not signal.
If AXP has underperformed the S&P 500 YTD, then a 6.89% increase in fund holdings would actually represent *outperformance* in accumulation—genuine conviction. The article doesn't provide AXP's YTD return or compare it to index weighting changes.
"13F ownership momentum is an unreliable near-term signal for AXP; real upside hinges on actual spend growth and credit quality, not fund-flow momentum."
News that 24 of 56 recent 13F filers hold AXP and aggregate holdings rose ~6.9% can signal institutional comfort with American Express as a high-quality, cash-generative financials franchise. But 13F data is lagging, long-only, and blind to shorts, options hedges, or reverse flows; the move may reflect mechanical factors like index rebalances or ETF flows rather than disciplined conviction. There’s no obvious near-term catalyst unique to AXP, and macro-driven consumer spend, travel demand, credit quality, and merchant mix will drive earnings more than fund-flow dynamics. Overall, this is a cautionary data point that supports a neutral stance rather than a clear buy.
The signal could be purely mechanical (index/ETF rebalancing) with little pricing power behind it; even if AXP benefits from a quality tilt, a consumer slowdown or rising credit losses could erase any modest multiple expansion.
"Institutional buying ignores the regulatory risk of AXP's premium merchant fee model, which is a greater threat than consumer credit cycles."
Claude is correct that 13F data is often mechanical, but both Claude and Gemini ignore the specific risk of the 'Amex-exclusive' merchant fee model. If the DOJ or FTC intensifies scrutiny on credit card network fees, AXP’s premium discount rate—its primary moat—faces a structural margin compression risk. Institutional buying might be a hedge against broader market volatility, but it ignores the regulatory headwinds that could decouple AXP from the broader S&P 500 financials performance.
"AXP's closed-loop model shields merchant fees from regulatory caps hitting open networks, supporting institutional conviction in resilient growth."
Gemini's DOJ/FTC risk ignores AXP's closed-loop moat: unlike Visa/MC's open networks, AmEx controls issuance and acceptance, sustaining premium discount rates (3.5-4% vs. peers' 2%) even under scrutiny. No major AXP-specific suits materialized post-Swain case. Overlooked: Q1 data showed 11% card spend growth from affluent travel, buffering any macro slowdown—explains 'smart money' net buying despite trims.
"AmEx's closed-loop model is defensible but not immune to regulatory re-pricing of discount rates, especially if affluent travel demand normalizes."
Grok's closed-loop moat argument is stronger than I credited, but it conflates two separate defenses. Yes, AmEx controls issuance—that's durable. But 'no major suits post-Swain' is weak comfort; the FTC's 2023 non-compete rule and ongoing scrutiny of fintech partnerships (Sofi, Square) suggest regulatory appetite is *rising*, not dormant. The 11% affluent travel spend is real, but it's also cyclical and priced in. Institutional buying could equally reflect flight-to-quality ahead of a consumer slowdown.
"Regulatory risk on merchant discount rates could compress AmEx margins, offsetting spend-driven upside from affluent travel and capping multiple expansion."
Particularly worth stressing is the regulatory risk around merchant discount rates. Grok focuses on AmEx's closed-loop moat; however, if the FTC/DOJ push toward open networks or cap fees, AmEx may be forced to absorb margin compression or raise member benefits, offsetting any upside from 11% affluent travel spend. The 6.9% holdings lift could be noise; what matters is resilience of margins, not just spend growth. This underappreciated risk could cap multiple expansion.
Panelists agree that 13F data has limitations and may not fully reflect institutional conviction towards AXP. They debate the significance of recent share increases, with some seeing it as a 'flight to quality' ahead of a potential slowdown, while others interpret it as a bullish signal. The regulatory risk around merchant discount rates is a key concern, potentially capping multiple expansion.
Potential re-rating if Q2 earnings confirm travel/cross-border strength, as suggested by Grok.
Regulatory risk around merchant discount rates, which could lead to margin compression or offset any upside from spend growth.